Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | TYR | P14679 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442434 | 0.81 | MAOB (0.52) | CA2CA12CA1CA9AKR1B1 | |
| SCHEMBL2122257 | 0.80 | CA2 (0.54) | CA2CAMK2AFNTAFNTBIDO1 | |
| SCHEMBL1160962 | 0.78 | CA2 (0.50) | CA2CAMK2AFNTAFNTBIDO1 | |
| SCHEMBL3119857 | 0.78 | CA2 (0.50) | CA2CAMK2AFNTAFNTBIDO1 | |
| SCHEMBL1160961 | 0.78 | CA2 (0.50) | CA2CAMK2AFNTAFNTBIDO1 | |
| SCHEMBL27949709 | 0.78 | KMT2A (0.51) | CA2CAMK2AFNTAFNTBIDO1 | |
| Chavicol SCHEMBL10525947 | 0.77 | XDH (0.47) | CA2CAMK2AFNTAFNTBESR1 | |
| SCHEMBL1707952 | 0.77 | KDM4E (0.57) | CA2SLC7A5CA12CA1CA3 | |
| Succinic Acid SCHEMBL729634 | 0.76 | CA2 (0.56) | CA2CAMK2AFNTAFNTBESR1 | |
| Chavicol SCHEMBL3119862 | 0.76 | CA2 (0.50) | CA2CAMK2AFNTAFNTBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | claimed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | claimed |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2020-03-17 | — | — | US | claimed |
| EP-3334710-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | Alzheon, Inc. (US) | 2018-06-20 | — | — | EP | claimed |
| CN-108026049-A | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | 阿尔泽恩股份有限公司 | 2018-05-11 | — | — | CN | claimed |
| WO-2017027582-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. (US) | 2017-02-16 | — | — | WO | claimed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-108026049-B | Compositions and methods for treating and preventing neurodegenerative disorders | 阿尔泽恩股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3334710-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | Alzheon, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-6037458-A | REMOVING APOLIPOPROTEINS FROM BODY FLUID IN A HUMAN SUFFERING FROM AMYLOIDOSIS; PASSING BODY FLUID THROUGH CONTAINER HAVING A FLUID INLET AND A FLUID OUTLET PACKED WITH AN ADSORBENT, RETURNING BODY FLUID PURFIED OF APOLIPROTEINS TO MAMMAL | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0476721-B1 | A method for removing serum amyloid protein | KANEGAFUCHI CHEMICAL IND (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5216127-A | Mixing body fluid containing serum amuloid protein with absorbent of water insoluble carrier and an amine, filtration and recovering protein | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0476721-A2 | A method for removing serum amyloid protein | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-03-25 | — | — | EP | disclosed |
| EP-0321703-A1 | Absorbent for serum amyloid protein | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-06-28 | — | — | EP | disclosed |
| US-4288364-A | REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE | CIBA-GEIGY CORPORATION (US) | 1981-09-08 | — | — | US | disclosed |
| EP-0005507-A1 | Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby | CIBA-GEIGY AG (CH) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | CA2 1709/4885CAMK2A 831/4885FNTA 2750/4885 |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | CA2 1709/4885CAMK2A 831/4885FNTA 2750/4885 |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | CA2 1709/4885CAMK2A 831/4885FNTA 2750/4885 |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | CA2 1709/4885CAMK2A 831/4885FNTA 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.